论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Yang S, Xing ZH, Liu T, Zhou J, Liang QH, Tang T, Cui HJ, Peng WJ, Xiong XG, Wang Y
Received 12 October 2017
Accepted for publication 12 December 2017
Published 6 March 2018 Volume 2018:12 Pages 463—473
DOI https://doi.org/10.2147/DDDT.S153927
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Palas Chanda
Peer reviewer comments 2
Editor who approved publication: Dr Anastasios Lymperopoulos
Background: Rheumatoid arthritis (RA) is a common worldwide public health
problem, which causes a chronic, systemic inflammatory disorder of synovial
joints. Paeoniflorin (PA) has achieved positive results to some extent for the
treatment of RA.
Purpose: This study aimed to reveal the potential druggable targets of PA in an
experimental RA model using quantitative proteomics analysis.
Study design
and methods: Thirty Sprague-Dawley
rats were randomly divided into a normal group, model group and PA group. PA (1
mg/kg) was used to treat collagen-induced arthritis (CIA) rats for 42 days. We
used isobaric tags for relative and absolute quantitation-based quantitative
proteomics to analyze the synovial tissue of rats. Ingenuity pathway analysis
(IPA) software was applied to process the data. The proteins that were targeted
via IPA software were verified by Western blots.
Results: We found that PA caused 86 differentially expressed proteins
(≥1.2-fold or ≤0.84-fold) compared with the CIA group. Of these varied
proteins, 20 significantly changed (p <0.05) proteins
referred to 41 CIA-relative top pathways after IPA pathway analysis. Thirteen
of the PA-regulated pathways were anchored, which intervened in 24 biological
functions. Next, network analysis revealed that leukemia inhibitory factor
receptor (LIFR) and asporin (ASPN), which participate in two significant
networks, contributed the most to the efficacy of PA treatment. Additionally,
Western blots confirmed the aforementioned druggable targets of PA for the
treatment of RA.
Conclusion: The results reveal that PA may treat RA by decreasing two key proteins,
LIFR and ASPN. Our research helps to identify potential agents for RA
treatment.
Keywords: paeoniflorin, quantitative proteomic, ASPN, LIFR, rheumatoid
arthritis